Product Images Jardiance

This appears to be a list of antidiabetic and other drugs, with their dosages and frequencies of administration. There is also a section at the end which contains some statistical data.*

This appears to be a list of various medications including antidiabetic drugs, oral contraceptives, and others. The medications listed include Metformin, Glimepiride, Piogitazone, Sitagliptin, Linagliptin, Etninyestradia, Levonorgestrel, Simvastatin, Warfarin, Ramipril, Ramipriat, Digoxin, Hydrochlorothiazide, and Torsemide. The list also includes dosage information for each medication. The remaining portion of the text appears to be data on the concentration of the medications in the body after administration, as well as a geometric mean ratio with a 90% confidence interval. No further context is given, so the usefulness of this information is limited.*

This is a table describing the mean change in HbA1C (%) from baseline in a study that administered placebo and two doses of empagliflozin (10mg and 25mg) to participants. The data is presented in 4-week intervals up to week 24, and the mean change is adjusted for baseline HbA1c, geographical region, and oGFR at baseline.*

The text format does not provide adequate information for generating a useful description.*

The text describes a clinical trial comparing Empagliflozin with a placebo in patients over a span of days since randomization. The incidence function was measured as % and the HR, P-value were also calculated. The data shows patients at risk over a period of 810 days since the beginning of the trial.*

This appears to be a chart or graph comparing the incidence function of a placebo group to a group taking empagliflozin 10 mg. There is also information on the patients at risk and the days since randomization. Without further context, it is difficult to provide a more specific description.*

This appears to be a graph or chart comparing the number of events and patients at risk for a placebo group and an Empagiflozin 10 mg group. The graph shows a reduction in events in the Empagiflozin group compared to the placebo group with a significant difference in P-value of 0.0009. The x-axis shows the number of days since randomization and the y-axis shows the number of patients at risk.*

This seems to be a table displaying various categories and their corresponding statistics related to diabetes, sex, race, GFR at baseline, NYHA at baseline, LVEF at baseline, NT-proBp, and baseline use of MRA. The text appears to be unreadable due to errors.*

This is a medication package for Jardiance tablets, with a total of 30 tablets divided into three blister cards, each containing 10 tablets. The package has a warning that it is not child-resistant and should be dispensed accordingly. There are two NDC codes provided, and the enclosed medication guide has been omitted. The rest of the text contains unclear characters and cannot be evaluated.*

This is a medication package of Jardiance (empagliflozin tablets) containing 30 tablets in 3 blister cards each with 10 tablets. The package contains a notice to dispense with the enclosed medication guide and two codes; NDC 0597-0153-37 and POL5458-004. Some of the characters are not recognizable.*